share_log

Aurinia Pharmaceuticals Gets European Commission Approval Of Lupkynis For The The Treatment Of Adults With Active Lupus Nephritis

Aurinia Pharmaceuticals Gets European Commission Approval Of Lupkynis For The The Treatment Of Adults With Active Lupus Nephritis

Aurinia制药公司获得欧盟委员会批准Lupkynis用于治疗成人活动性狼疮性肾炎
Benzinga Real-time News ·  2022/09/15 12:04

Aurinia Pharmaceuticals Gets European Commission Approval Of Lupkynis For The The Treatment Of Adults With Active Lupus Nephritis

Aurinia制药公司获得欧盟委员会批准Lupkynis用于治疗成人活动性狼疮性肾炎

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发